Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) is projected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.24 per share and revenue of $92.1070 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03). Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%.The firm had revenue of $47.71 million for the quarter, compared to analysts' expectations of $86.10 million. On average, analysts expect Ironwood Pharmaceuticals to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Ironwood Pharmaceuticals Stock Performance
Shares of NASDAQ IRWD opened at $4.20 on Wednesday. The company has a market capitalization of $684.84 million, a PE ratio of 32.31 and a beta of 0.17. Ironwood Pharmaceuticals has a 1 year low of $0.53 and a 1 year high of $5.78. The company's fifty day moving average price is $3.68 and its 200 day moving average price is $3.53.
Insider Transactions at Ironwood Pharmaceuticals
In related news, Director Alexander J. Denner sold 6,730,800 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total transaction of $20,528,940.00. Following the completion of the sale, the director directly owned 9,188,635 shares in the company, valued at approximately $28,025,336.75. This trade represents a 42.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.70% of the company's stock.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC boosted its stake in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company's stock worth $25,000 after buying an additional 3,406 shares during the period. Captrust Financial Advisors purchased a new position in shares of Ironwood Pharmaceuticals in the second quarter valued at approximately $32,000. Jump Financial LLC purchased a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $34,000. Cibc World Markets Corp purchased a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Vise Technologies Inc. purchased a new position in Ironwood Pharmaceuticals in the third quarter worth approximately $39,000.
Wall Street Analyst Weigh In
Several research firms have issued reports on IRWD. Wall Street Zen downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 7th. Citigroup raised shares of Ironwood Pharmaceuticals from a "market perform" rating to an "outperform" rating in a report on Monday, January 5th. Citizens Jmp increased their price objective on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a "market outperform" rating in a report on Thursday, February 26th. Craig Hallum raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, January 5th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $3.70 target price on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has an average rating of "Hold" and an average target price of $6.23.
View Our Latest Research Report on Ironwood Pharmaceuticals
About Ironwood Pharmaceuticals
(
Get Free Report)
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company's flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ironwood Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.
While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
